Early investigations discovered that IL-22 polymorphisms were related to an increased risk of developing CRC, which was later confirmed in human CRC studies that IL-22 was significantly expressed in tumor tissue and associated with chemoresistance responses (129). Here, IL22 is linked to colorectal carcinoma.